158 filings
Page 3 of 8
DEFA14A
5iwriv0
30 Apr 18
Additional proxy soliciting materials
4:37pm
CT ORDER
i2fecc2rt 8a
16 Apr 18
Confidential treatment order
12:00am
S-8
13qd7t8c
1 Mar 18
Registration of securities for employees
12:00am
8-K
nu9rg
1 Mar 18
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results
12:00am
8-K
zij53ak8l0ebx bq4vde
21 Feb 18
Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
12:00am
8-K
s7d0 t713ra9
8 Jan 18
Regulation FD Disclosure
12:00am
8-K
7rn w0lnu
27 Dec 17
Departure of Directors or Certain Officers
12:00am
8-K
373n9
4 Dec 17
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
12:00am
8-K
f5em1
21 Nov 17
Entry into a Material Definitive Agreement
12:00am
CT ORDER
52i iovv1rlz
20 Nov 17
Confidential treatment order
12:00am
8-K
getif6
14 Nov 17
Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195
12:00am
8-K
lx12c5rdvoc r7k33gd
2 Nov 17
Results of Operations and Financial Condition
12:00am
8-K
fiawj xjmda
18 Oct 17
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
12:00am
8-K
mznz9 53c
18 Oct 17
Regulation FD Disclosure
12:00am
8-K
ouleuxk2
28 Sep 17
Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer
12:00am
8-K
kr52i7vvcchr6ile1g
8 Aug 17
Results of Operations and Financial Condition
12:00am